CADTH Canadian Drug Expert Committee final recommendation: Tiotropium/Olodaterol (Inspiolto Respimat - Boehringer Ingelheim Canada Ltd.) indication : chronic obstructive pulmonary disease
The CADTH Canadian Drug Expert Committee (CDEC) recommends that tiotropium/olodaterol (TIO/OLO) be listed for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysem...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
December 17, 2015, 2015
|
| Series: | Common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that tiotropium/olodaterol (TIO/OLO) be listed for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema |
|---|---|
| Physical Description: | 1 PDF file (7 pages) |